The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics.
group A Streptococcus
pharyngitis
rheumatic heart disease
vaccine
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
16 08 2019
16 08 2019
Historique:
received:
26
09
2018
revised:
05
11
2018
accepted:
07
01
2019
pubmed:
10
1
2019
medline:
18
9
2020
entrez:
10
1
2019
Statut:
ppublish
Résumé
Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.
Identifiants
pubmed: 30624673
pii: 5280612
doi: 10.1093/cid/ciy1143
pmc: PMC6695511
doi:
Substances chimiques
Streptococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
877-883Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Vaccine. 2011 Oct 26;29(46):8175-8
pubmed: 21920403
BMC Infect Dis. 2010 Nov 11;10:327
pubmed: 21070669
Am J Cardiovasc Drugs. 2013 Feb;13(1):1-4
pubmed: 23355360
Mol Cell Proteomics. 2012 Jun;11(6):M111.015693
pubmed: 22286755
J Clin Microbiol. 2008 Jul;46(7):2359-67
pubmed: 18463210
N Engl J Med. 2017 Aug 24;377(8):713-722
pubmed: 28834488
Curr Opin Obstet Gynecol. 2013 Apr;25(2):109-16
pubmed: 23385771
J Invest Dermatol. 2014 Jun;134(6):1527-1534
pubmed: 24166134
Lancet Infect Dis. 2011 Sep;11(9):692-701
pubmed: 21659004
PLoS One. 2018 Jul 2;13(7):e0198658
pubmed: 29965967
Immunology. 1996 Nov;89(3):331-7
pubmed: 8958044
Curr Opin Infect Dis. 2012 Apr;25(2):145-53
pubmed: 22327467
Vaccine. 2018 Jun 7;36(24):3397-3405
pubmed: 29496349
JAMA. 1969 Feb 10;207(6):1115-9
pubmed: 5818242
PLoS One. 2015 Aug 28;10(8):e0136789
pubmed: 26317533
Emerg Infect Dis. 2016 Feb;22(2):224-32
pubmed: 26811918
Circulation. 2009 Aug 25;120(8):709-13
pubmed: 19667233
Hum Vaccin Immunother. 2018 May 4;14(5):1118-1130
pubmed: 29565712
Lancet Infect Dis. 2009 Oct;9(10):611-6
pubmed: 19778763
J Infect Dis. 2014 Oct 15;210(8):1325-38
pubmed: 24799598
AMA Am J Dis Child. 1953 Sep;86(3):347-8
pubmed: 13091327
Infect Immun. 2002 Apr;70(4):2171-7
pubmed: 11895984
JAMA. 2000 Dec 13;284(22):2912-8
pubmed: 11147989
Clin Microbiol Rev. 2000 Jul;13(3):470-511
pubmed: 10885988
JAMA Pediatr. 2014 Nov;168(11):1073-4
pubmed: 25264869
J Exp Med. 1959 Aug 1;110(2):271-92
pubmed: 13673139
J Immunol Res. 2015;2015:167089
pubmed: 26101780
JAMA Intern Med. 2014 Jan;174(1):138-40
pubmed: 24091806
Lancet Infect Dis. 2005 Nov;5(11):685-94
pubmed: 16253886
Vaccine. 2017 Apr 11;35(16):2007-2014
pubmed: 28318768